Antoine Papiernik

will need a specific treatment if you want to be active.

We are most active in Europe.

I forgot to answer your question.

70% of what we do is in Europe, 30% in the U.S.

So if we can leverage the best of the U.S., and there's so much things that are amazing in the U.S.

on the biotech side, and the best of China in order to do the best of Europe, this is the way we're thinking about this.

Yeah, you know, we sold Amoled, a French company in Lyon, to AstraZeneca last year.

You know, we happened, you know, in developing a drug that's now demonstrated, you know, it worked in phase three.

So that's always nice.

It's nice to sell a company for euros, a big number, but it's also super nice to see that that drug actually panned out.

I think about Syncor as well, another company that we sold to AstraZeneca.

where, you know, they had phase three results recently in resistant hypertension.

And, you know, it's always, it's financially important for us because you get to learn out if you hit the milestone.

But it's also super interesting that you have a chance to change standard of care.

You know, it's like, this is done like this before a drug, and then you have a new drug, and that changes the standard of care.

I mean, this year, of course, and it's not an exit, but it's a public huge success.

That's Abivax, of course, if you think about it.

abivax was this company that was not doing great for a long time on on european public market and then went public on on nasdaq you know still had it was had the had the pressure of this european companies that hasn't yet demonstrated that its product works and look what happens when when you come out with you know phase three results that is absolutely clear-cut and everyone needs to recognize wow this could be a major drug

And well, you know, we are.

Not me, but my partner Kinam is still on the board of that company.